Subscribe To
RLAY / Relay Therapeutics Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3Kα
Content Topics
Relay
Therapeutics
Announces
Preclinical
Data
That
Support
Rly 2608
Allosteric
Pan mutant
Selective
Inhibitor
Pi3k
Stock
RLAY
RLAY News
By GlobeNewsWire
September 18, 2023
Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming more_horizontal
By Zacks Investment Research
August 8, 2023
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates
Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compare more_horizontal
By Seeking Alpha
July 28, 2023
Relay Therapeutics: Market May Be Prematurely Dismissing RLY-2608
Relay Therapeutics' early clinical data for cancer drug RLY-2608 sparked investor concerns due to lack of robust evidence of efficacy, leading to a 40 more_horizontal
By Zacks Investment Research
May 4, 2023
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Misses Revenue Estimates
Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compare more_horizontal
By Zacks Investment Research
April 14, 2023
Relay Therapeutics, Inc. (RLAY) Surges 13.8%: Is This an Indication of Further Gains?
Relay Therapeutics, Inc. (RLAY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions mi more_horizontal
By Zacks Investment Research
April 6, 2023
Wall Street Analysts Think Relay Therapeutics, Inc. (RLAY) Could Surge 94.78%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 94.8% in Relay Therapeutics, Inc. (RLAY). While the effective more_horizontal
By GlobeNewsWire
March 1, 2023
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this mo more_horizontal
By Seeking Alpha
January 18, 2023
Relay Therapeutics: Tall Claims, Some Proofs Of Concept, Some Concerns
Relay Therapeutics, Inc. discovers drugs using a novel computational approach. There is some proof of concept data. more_horizontal